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Abstract
Background: It was reported that metastases might occur via transfer of biologically active blood circulating molecules
from the primary tumor to distant organs rather than only migration of cancer cells. We showed in an earlier study that
exposure of immortalized human embryonic kidney cells (HEK 293) to cancer patient sera, induce their transformation
into undifferentiated cancers due to a horizontal transfer of malignant traits. In the present work, we tested the
hypothesis that even other human cells as long as they are deficient for a single oncosuppressor gene might undergo
malignant transformation when exposed to human cancer serum.
Methods: We used the CRISPR/Cas9 system to establish a stable BRCA1 knockout (KO) in human fibroblasts. The
BRCA1-KO fibroblasts were exposed to cancer patients’ sera or healthy patients’ sera for 2 weeks. Treated cells
were analyzed for cell proliferation and transformation to study their susceptibility to the oncogenic potential of
cancer patients’ sera and to determine the possible mechanisms underlying their hypothesized transformation.
Results: BRCA1-KO fibroblasts treated with cancer patients’ sera displayed higher proliferation and underwent
malignant transformation as opposed to wild type control fibroblasts, which were not affected by exposure to
cancer patients’ sera. The malignant transformation was not seen when BRCA1-KO fibroblasts were treated with
healthy human sera. Histological analysis of tumors generated by BRCA1-KO fibroblasts showed that they were
carcinomas with phenotypical characteristics related to the cancers of the blood donor patients. Interestingly,
BRCA1-KO fibroblasts were significantly more prone to internalize serum-derived exosomes, when compared to
wild type fibroblasts. This suggests that oncosuppressor genes might protect the integrity of the cell genome
also by blocking integration of cancer-derived exosomes.
Conclusion: These data support the hypothesis that any human cells carrying a single oncosuppressor mutation
is capable of integrating cancer factors carried in the blood and undergo complete malignant transformation.
Oncosuppressor genes might protect the cell genome by impeding the integration inside the cells of these
mutating factors.
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Background
Metastasis is considered the leading cause of morbidity
and mortality related to cancer [1, 2]. It has been well
accepted that metastases develop by dissemination of
cancer cells, which detach from the primary tumors,
travel through the circulatory system and reach the
metastatic site where they start to grow [3]. A review of
recent literature brought evidence that the metastatic
process might not be only due to primary tumor cells
spreading to distant metastatic sites. Several studies re-
ported that cancer cells-derived factors could either pre-
pare a niche to permit the engraftment of malignant
cancer cell in distant organs or predispose target cells,
located in distant organs, to their malignant transform-
ation [4–9]. These factors (i.e., proteins, nucleic acids,
cell-surface receptors and lipids) could be either blood
floating naked entities or molecules carried as cargo in
exosomes [5, 7, 10–16].
Exosomes are small (30–100 nm) extracellular
membrane-enclosed vesicles, which originate from cellu-
lar endosomal compartment under both physiological
and pathological conditions [17–19]. Exosomes, which
express distinctive surface markers, harbour substances
that mirror the content of their cell of origin [20–22]
and have the capability to induce different types effects,
even at distance, by insuring the trafficking of different
factors (i.e., survival and mitogenic signalling molecules)
into target recipient cells [4, 8].
Pioneer researchers describing malignant trait transfer
via blood circulating factors in immortalized mouse fibro-
blasts (NIH3T3 cells) called this phenomenon “genome-
tastasis” [23–25]. Recently, after exposing immortalized
human embryonic kidney cells (HEK293) to cancer pa-
tients’ sera, we observed their transformation into malig-
nant cells, confirming for the first time the validity of the
genometastatic theory in human cells [26]. In our study
we remarked that only HEK293 were prone to undergo
malignant transformation as opposed to different types of
normal cells (fibroblasts, mesenchymal stem cells and em-
bryonic stem cells), which failed to acquire the malignant
traits.
Our findings supported the hypothesis that the differ-
ent stages of carcinogenesis such as initiation, promo-
tion and progression might not represent events limited
to the cells forming the primary tumor, but may actually
be a process reproducible in primed cells, located in tar-
get organs, through the incorporation of key factors
released by the primary tumor. To strengthen our hy-
pothesis that any cell with a single oncosuppressor mu-
tation might be susceptible to integrate mutating factors
at metastatic sites, we generated a human fibroblast cell
line deficient for the oncosuppressor BRCA1 (Breast
cancer susceptibility gene 1) using the CRISPR technol-
ogy and we exposed it to different types of patients’
cancer sera and healthy patients’ sera. BRCA1 is a tumor
suppressor gene that plays a significant role in DNA re-
pair pathways [27]. Specific inherited mutations in
BRCA1 increase the risk of breast and ovarian cancers,
and it has been associated with increased risks of several
additional types of cancer [28–30].
The aims of our investigations were to determine the
oncogenic potential of cancer patients’ sera on BRCA1-
KO human fibroblasts, to characterize their differenti-
ation following serum treatments and evaluate their
phenotypes, and to determine their receptiveness to
integrate serum-carried factors, such as exosomes.
BRCA1-KO fibroblasts treated with cancer patients’ sera
displayed higher proliferation and underwent malignant
transformation as opposed to wild type fibroblasts,
which were not affected by exposure to cancer patients’
sera. The malignant transformation was not seen when
BRCA1-KO fibroblasts were treated with healthy human
sera. Histological analysis of tumors generated by
BRCA1-KO fibroblasts showed that they were carcin-
omas with phenotypical characteristics related to the
cancers of the blood donor patients. Uptake of exosomes
was significantly higher in the oncosuppressor mutated
cells.
Methods
Patients’ recruitment and characteristics of cancers
Patients for the current study were recruited form the
department of General Surgery at the Royal Victoria
Hospital and St-Mary’s Hospital (Montreal, Canada) and
underwent a written consent for blood collection in ac-
cordance to a protocol approved by the Ethics Commit-
tee of our institution (SDR-10-057). Blood samples were
collected from both healthy individuals and patients who
underwent resection of primary cancer and who were re-
admitted for metastatic disease treatment (Table 1).
Healthy subjects were recruited based on three criteria:
(i) age (35–45-year-old), (ii) absence of any signs and
symptoms or personal history of cancer and (iii) negative
family history for malignancy.
Blood collection and serum preparation from cancer
patients and healthy subjects
Blood samples (20 ml) were collected from a peripheral
vein in vacutainer tubes (Becton Dickinson) containing
clot-activation additive and a barrier gel to isolate serum.
Blood samples were incubated for 60 min at room
temperature to allow clotting and subsequently were
centrifuged at 1500 g for 15 min. Serum was collected
and a second centrifugation was performed on the
serum at 2000 g for 10 min to clear it from any contam-
inating cells. Serum samples were aliquoted and stored
at −80 °C until use.
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Cell line and culture conditions
Human fibroblasts and human embryonic kidney cells
(HEK-293) (ATCC, VA, USA) were maintained as per
supplier’s recommendations. When cells reached 30 %
confluence, they were treated with DMEM-F12 medium
(Wisent, Saint-Bruno, Canada) supplemented with anti-
biotics and 10 % cancer patient sera or control sera,
which had been filtered through 0.2 μm filters. Cells
were maintained in these conditions at 37 °C in humidi-
fied atmosphere containing 95 % air and 5 % CO2 with
medium change every second day for 2 weeks. When
cells reached 80-90 % confluence, they were passaged 1
in 6 using 0.05 % Trypsin-EDTA (Wisent, Saint-Bruno,
Canada). To confirm that there was no contamination
or carry-over of cells from human serum, aliquots of the
culture medium were placed in a culture plate and incu-
bated at 37 °C, 5 % CO2 for 4 weeks.
CRISPR/Cas9-mediated BRCA1 knockout in fibroblasts and
cell sorting
We used the CRISPR/Cas9 system to establish a stable
BRCA1 knockout in human fibroblasts as previously de-
scribed [31]. The pSpCas9(BB)-2A-GFP plasmid (PX458;
Addgene, MA, USA) was used as the cloning backbone
for sgBRCA1 (single-guided RNA to BRCA1). For this
study, we designed two sequences targeting BRCA1
locus (Table 2). Human fibroblasts were transfected with
the empty plasmid (PX458) or the plasmid containing
the guide (PX458-sgBRCA1) using Lipofectamine 3000 as
per the manufacturer protocol (Invitrogen, Burlington,
Canada). Transfected fibroblasts were then sorted based
on the expression of the reporter GFP (green fluorescent
protein) gene using a FACSAria cytometer (BD Biosci-
ences, Mississauga, Canada) (Additional file 1: Figure S1).
Sorted GFP positive cells were cultured and aliquots were
subjected to Surveyor assay and Western blot analyses
(Additional file 2: Figure S2). To minimize the off-target
effects, cells were transfected with minimal amount of
plasmid (500 ng). Also, the guide sequences were designed
by using a web-based prediction algorithm tool [31]. We
chose the highly ranked guide sequence with the least ex-
onic off-target sites (Additional file 3: Table S2 and S3).
SURVEYOR nuclease assay
DNA was isolated from sorted fibroblasts using GenElute
Mammalian Genomic DNA Miniprep kit according to
manufacturer specifications (Sigma, Oakville, Canada). Ex-
tracted DNA was amplified by PCR using Phusion High-
Fidelity PCR kit (NEB, MA, USA) and set of primers for
BRCA1 gene (Table 2). The PCR reaction was performed
in thermal cycler (Bio-Rad Laboratories, Inc., Hercules,
CA, U.S.A.). Amplicons were loaded on 1 % agarose gel
and corresponding bands with the expected sizes were ex-
cised and purified using QIAquick Gel Extraction Kit
(QIAGEN, Redwood City, CA, USA). Purified DNA sam-
ples were subjected to the Indel (insertion/deletion) assay.
Briefly, DNA was denatured at 95 °C for 10 min, and let
anneal at decreasing temperatures (95 °C to 20 °C) for
30 min. Reannealed DNA was subjected to endonuclease
digestion using IDT Surveyor Mutation Detection kit
(IDT, Iowa, USA). The digestion products were run on
1 % agarose gel to quantify the Indel efficiency (Additional
file 2: Figure S2) [31]. Briefly, the gel was imaged and the
intensity of the bands in each lane was measured by using
ImageJ Software. For each lane, we calculated the fraction
of the PCR product cleaved by using the following for-
mula: fcut = (B +C)/(A + B + C), where A is the intensity
Table 1 Clinical features of cancer patients recruited in the present study
Cases Age (y) Gender Tumor
A 70 Female Adrenal corticocarcinoma - Lung Metastasis
B 69 Female Breast cancer - Lung & Liver Metastasis
C 60 Female Metastatic poorly differentiated neuroendocrine carcinoma
D 45 Female Breast cancer - Liver Metastasis
E 66 Male Colorectal cancer - Liver Metastasis
F 66 Male Anal squamous cell carcinoma – Liver Metastasis
G 65 Male Colorectal cancer - Liver Metastasis
H 72 Female Colorectal cancer - Liver Metastasis
I 64 Female Colorectal cancer - Liver Metastasis
J 73 Male Pancreatic cancer
Table 2 Primers sequences used in sgBRCA1 cloning and
knockout validation




hU6_Seq ACTATCATATGCTTACCGTAAC Primer for sequencing
BRCA1-F TAGGGGTGGATATGGGTGAA Surveyor assay
BRCA1-R GTTGCAGTGAGCCAAGATCA Surveyor assay
aThese oligos were annealed to make the double-stranded linker with sticky
ends (underlined nucleotides)
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of the undigested PCR product, while B and C are the in-
tensities of each cleaved band. The Indel percentage was
estimated by applying the following formula:




Population doubling level (PDL) calculation
Cells were considered at population doubling zero at the
first time they are exposed to patient serum-containing
culture medium. At every passage, cell number was de-
termined and population doubling was calculated using
the following formula; PDL = log(Nh/Ni)/log2, where Nh
is the number of cells harvested at the end of the incu-
bation time and Ni is the number of cells inoculated at
the beginning of the incubation time. Cumulative PDL
was calculated by adding the previous calculated PDL.
Immunoblotting
Cells were lysed in RIPA buffer containing protease in-
hibitors (Sigma, Oakville, Canada). Equal amounts of
proteins were resolved on 10 % SDS-PAGE and trans-
ferred to a nitrocellulose membrane (BioRad, CA, USA).
Membranes were blocked in TBS containing 5 % non-fat
dry milk and exposed overnight at 4 °C to rabbit-anti-
BRCA1 (ab191042 and ab131360, Abcam, MA, USA) or
mouse-anti-β-Actin (A5316, Sigma, Oakville, Canada).
Membranes were washed in TBST (TBS-0.05 % Tween-
20) and incubated with either anti-rabbit or anti-mouse
peroxidase-conjugated secondary antibody for 1 h at
room temperature. After several washes in TBST, the
blots were developed using Immobilon Western HRP
Substrate (Millipore, Etobicoke, Canada).
Exosomes isolation and labeling
Exosomes were isolated from serum using Total Exo-
some Isolation kit according to the manufacturer’s
protocol (Invitrogen, Burlington, Canada). Exosomes
were labeled using the PKH26 dye following the manufac-
turer recommendations (Sigma, Oakville, Canada). La-
beled exosomes were diluted in labeling stop solution
(PBS/FBS) and pelleted by ultra-centrifugation for 80 min
at 100,000 x g at 4 °C. The pellet was washed in Hank's
Balanced Salt Solution (HBSS) with an ultra-centrifugation
using the same parameters. The pelleted exosomes were
re-suspended in HBSS and stored at −80 °C. 10 μg of
labeled exosomes was added to ~5x103BRCA1-KO
Fibroblast, Control PX-458-transfected fibroblasts and
HEK-293 cells cultured in 8-well chamber slides (VWR,
Mont-Royal, Canada). Cells were washed, fixed for 10 min
with Paraformaldehyde 4 %. Slides were mounted with
coverslip in VECTASHIELD Mounting Medium with DAPI
(Vector Laboratories, Burlington, Canada). Stained cells
were visualized using an LSM780 confocal microscope
(Zeiss, Toronto, Canada). Exosomes internalization was
quantified using ImageJ software.
Exosomes characterization
Morphological examination of isolated exosomes was
done using transmission electron microscope (JEM-
2010, Jeol Ltd., Tokyo, Japan). Briefly, 20 μl of exosomes
were loaded on a copper grid and stained with 2 % phos-
photungstic acid. Samples were dried by incubating
them for 10 min under an electric incandescent lamp.
Samples were examined under electron microscope and
imaged using a Hitachi H-600 TEM operating at 60 kV.
In Parallel, an aliquot of exosome samples was run on a
Nanosight NS500 system (Nanosight Ltd., Amesbury,
UK), and size distribution was analyzed using the NTA
1.3 software.
In vivo tumor growth
Five-week-old female NOD-SCID mice (Jackson Labora-
tory) were used in compliance with McGill University
Health Centre Animal Compliance Office (Protocol 2012–
7280). Cells growing in log phase were harvested by trypsi-
nization and washed twice with HBSS. Mice were injected
subcutaneously with 2 million cells in 200 μl HBSS/Matri-
gel. Mice were euthanized one month post-injection. The
resulting xenotransplants were photographed and proc-
essed as indicated below.
Immunohistochemistry labelling procedures and
histological analyses
Mice xenotransplants were collected, fixed in 10 % buff-
ered formalin, embedded in paraffin, and stained with
H&E (hematoxylin and eosin) according to standard pro-
tocols or processed for immunohistochemistry. Briefly,
5 μm tissue sections were dewaxed in xylene and rehy-
drated with distilled water. After antigen unmasking, and
blocking of endogenous peroxidase (3 % hydrogen perox-
ide), the slides were incubated with primary antibodies
(Additional file 3: Table S1). Labeling was performed using
iView DAB Detection Kit (Ventana) on the Ventana
automated immunostainer. Sections were counterstained
lightly with Hematoxylin before mounting. Histological
analyses were performed by a certified pathologist who
was blinded to the type of cells from which the cancerous
masses, which formed in mice, had been derived.
Statistical analysis
Statistical analysis Statistical differences were analyzed
using Student’s t test for unpaired samples. An ANOVA
followed by the Dunnett test was used for multiple com-
parisons with one control group. The criterion for sig-
nificance (p value) was set as mentioned in figures.
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Results
BRCA1 knocking-out in human fibroblasts
A human fibroblast cell line deficient for the oncosup-
pressor BRCA1 was developed to study its susceptibility
to the oncogenic potential of cancer patient serum
(Additional file 1: Figure S1A). For this purpose, we used
the CRISPR-Cas9 technology to knock-out BRCA1 [31].
BRCA1-KO fibroblasts (i.e., fibroblasts transfected with
a sgBRCA1-expressing vector) and control fibroblasts
(empty vector transfected cells) were sorted based on
the expression of the GFP reporter gene (Additional file
1: Figure S1B). BRCA1 knockout was validated using the
SURVEYOR nuclease assay (Additional file 2: Figure
S2A). One of two guides used was efficient in knocking-
out BRCA1 in fibroblasts. As described in Materials and
Methods, the Indel percentage was estimated at 33 %,
which is in the range of the values obtained with this
assay. Moreover, protein extracts were analyzed for
BRCA1 expression. BRCA1 was not detected in BRCA1-
KO fibroblasts, compared to empty vector-transfected
cells (Additional file 2: Figure S2B).
Cancer patient sera increased the proliferation of BRCA1-
KO fibroblasts
To analyze the effect of cancer patient sera on the growth
of BRCA1-deficient fibroblasts, equal amount of cells were
plated and cultured with DMEM media supplemented
with 10 % of cancer patients’ serum for 2 weeks. We used
serum from two healthy control donors and 10 metastatic
cancer patients (Table 1). At every passage, cell numbers
were determined to estimate the population doubling
levels (PDL) in each condition (Fig. 1a). Independently of
the cancer serum used, the cumulative PDL was increased
when compared to that of cells cultured in control human
serum (range: 1.3 to 6.1 increase in population doubling;
mean +/− SD: 3.2 +/− 1.4; P = 0.027) (Fig. 1b). These data
suggest that cancer patient sera significantly enhanced the
proliferation of BRCA1-deficient fibroblasts in vitro.
Cancer patients’ sera transfer malignant traits to BRCA1-KO
fibroblasts
To determine whether cancer sera promote tumor for-
mation in vivo, NOD/SCID mice were injected subcuta-
neously with BRCA1-KO fibroblasts exposed to healthy
control or cancer patients’ sera. Cells were injected fol-
lowing 2 weeks of treatment. Mice were followed up for
tumor growth, and they were euthanatized 3 to 4 weeks
after cell inoculation due to the massive growth of can-
cerous masses, which had compromised the ability to
move of the mice. Independently of the cancer serum
used, all mice injected with cancer sera-treated BRCA1-
KO fibroblasts developed visible tumors as early as one
week following inoculation (Fig. 2a and Additional file 4:
Figure S3). In contrast, none of the mice injected with
control fibroblasts, treated with healthy control or can-
cer patient sera, developed tumors during the course of
the experiments (4 weeks latency) (Fig. 2a).
Histopathological analyses of excised tumors showed
solid growth of tumor cells sheets with high proliferation
index (over 85–90 % Ki67 positivity) (Fig. 2b, c and Add-
itional file 5: Figure S4). We further characterized these
tumors for differentiation patterns based on the primary
tumor of the blood donors. The histology of tumors ob-
tained with cells treated with sera derived from five dif-
ferent patients (Cases A, B, C, D and F) confirmed that
they were poorly differentiated carcinomas (Fig. 3 and
Additional file 4: Figure S3). Notably, vimentin staining
of all the cancerous masses was negative indicating that
cancer factors carried in the sera of all tested patients
had integrated in the genome of the BRCA1-KO fibro-
blasts changing their fate permanently. Even more strik-
ing was the discovery that BRCA-KO fibroblasts treated
with sera taken from four patients with colorectal cancer
liver metastases (Cases E, G, H and I), and one patient
with pancreatic cancer (Case J) displayed epithelial differ-
entiating features typical of colorectal adenocarcinomas
and pancreatic ductal adenocarcinoma, respectively
(Table 3 and Fig. 2b, c and Additional file 5: Figure S4).
The tumors generated with cells treated with cases E, G,
H and I (colorectal cancer) were negative for CK7 but they
all stained positive for CEA, CK20, CDX-2 and AE1/AE3,
which are universal markers of colorectal cancer. The tu-
mors generated with BRCA-KO fibroblasts treated with
a b
Fig. 1 Cancer patient sera increased BRCA1-KO fibroblasts growth.
Cells were cultured for 2 weeks in control human serum, or cancer
patient sera. Cell growth was then analyzed by counting the number
of viable cells at every passage (5 days duration for every passage).
a Line graph shows the population doublings capability and (b) column
graph represents cumulative population doublings at the end of the
treatment periods. Data are mean ± SD of 2 control sera vs. 6 cancer
patient sera. (P= 0.027)
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case J (pancreatic cancer), stained strongly positive for
CK7/CK19 which is a typical feature of pancreatic adeno-
carcinoma differentiation. Interestingly, CK7 expression
was not uniform in the cancer specimen but it was
strongly expressed in the areas with pancreatic tumor
morphology indicating an evolving differentiation from
undifferentiated morphology to pancreatic cancer pheno-
type. Attempts to characterize immunohistochemically the
other tumors failed to show any differentiating features re-
sembling the tumors of blood donors as they all stained
negatively for tumor-specific markers (Table 3 and Fig. 3).
BRCA1-KO fibroblasts treated with healthy control sera
failed to acquire any malignant transformation
To rule out the possibility that BRCA1-KO fibroblasts
might have an innate tendency to turn malignant due to
the impaired function of the BRCA1 gene, BRCA1-KO
fibroblasts were cultured with healthy patients’ serum for
2 weeks. Inoculation of these cells in NOD/SCID mice
failed to form any mass even at longer latency period
(12 weeks post-transplantation), confirming the known
notion that a single oncosuppressor mutation is not
enough to trigger cancerogenesis and activate the cascade
of events that eventually lead to cancer transformation
(Fig. 2a). Furthermore, the results of this test confirmed
also that the putative factors responsible for the malignant
transformation of the BRCA1-KO fibroblasts were exclu-
sively present in the serum of patients with metastatic
cancer and were absent in the serum of healthy patients.
Malignant transformation of the BRCA1-KO fibroblasts is
permanent and not transient
Further, we wanted to test whether the malignant trans-
formation of the BRCA1-KO fibroblasts was permanent
Fig. 2 Cancer patient sera induced the transformation of BRCA1-KO fibroblasts. a NOD/SCID mice were injected with either control or BRCA1-KO
fibroblasts, that were treated for 2 weeks with healthy individual (Control) or cancer patient sera. 4 weeks after cells transplantation, mice were
euthanized and the tumors photographed. Representative pictures are shown. Tumor masses were only observed when mice were injected with
BRCA1-KO fibroblasts treated with cancer patient sera. (n = 3 mice per group). (b and c) Formalin-fixed paraffin-embedded tumors generated
following injection of BRCA1-KO fibroblasts treated with CRC-LM patient serum (b: Case E) or pancreatic cancer patient serum (c: Case J) were
processed for H&E staining, or immunolabeled with antibodies against tumor specific markers
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and not secondary to a short-term and transient effect.
Therefore, BRCA1-KO fibroblasts were treated with can-
cer serum for 2 weeks. Subsequently, they were exposed
to DMEM-F12 media supplemented with 10 % FBS and
1 % Pen-Strep, for two more weeks to allow them to re-
cover. Interestingly we found that cells had kept their
tumorigenic potential and still formed tumors when they
were injected into NOD/SCID mice, indicating thus that
the transformation was indeed permanent and not tran-
sient (Fig. 4).
BRCA1-KO fibroblasts demonstrate a significant increased
uptake of cancer-derived exosomes
A number of recent evidences indicate that exosomes
are involved in cancer invasion and metastasis [4, 8, 18,
32]. We had noticed in previous unpublished experi-
ments that cancer exosomes had the tendency to accu-
mulate in the cytoplasm of HEK293 cells in larger
number than what was observed in normal cells. Follow-
ing this observation, we hypothesized that perhaps one
of the methods implemented by the oncosuppressor
genes to protect the genome of the cells was to prevent
the uptake of genetic material potentially harmful to the
cell. As a consequence of that, any cell with a single
oncosuppressor mutation would show a superior uptake
of cancer exosomes. In order to test our hypothesis,
exosomes were isolated from cancer patients’ sera. The
size of the isolated particles was between 50 and 120 nm
as visualized by electron microscopy (Fig. 5a), and Nano-
sight analyses (size = 103 +/− 7; Fig. 5b). This is in the
range of the expected size for exosomes. The isolated
exosomes were labeled with PKH-26 and added to
BRCA1-KO and wild type fibroblasts, and HEK293 cell
cultures to assess their internalization. Exosomes uptake
was assessed by measuring the number of positive intra-
cellular spots (Fig. 5c and d). As hypothesized, BRCA1-
KO fibroblasts and HEK293 cells showed an uptake of
cancer exosomes 3 to 13 times higher (6.6 +/− 0.6 times
for BRCA1-KO fibroblasts and 7.7 +/− 2.0 for HEK293
cells) than that measured in control wild type fibroblasts.
This suggests that one of the ways oncosuppressor genes
might use to protect the integrity of the genome would
be to act as gatekeepers at the membrane level and block
the integration of dangerous genetic material.
Discussion
In the present study, we confirmed that sera of patients
with metastatic cancer contain tumorigenesis-signaling
factors that, once delivered to recipient target cells, are
capable to complete the cascade of events that eventu-
ally lead the cells to acquire malignant traits. In our pre-
vious research we had used the HEK293 cells as a model
Fig. 3 Tumors generated with cancer patient sera-treated BRCA1-KO did not all display differentiation characteristics. BRCA1-KO fibroblasts were
treated with cancer patient sera for 2 weeks (Cases A, B, C, D, and F). Treated cells were injected into NOD/SCID mice that were followed for
4 weeks for tumors growth. Developing tumors were excised and photographed (See Additional file 4: Figure S3). Formalin-fixed paraffin-embedded
xenotransplant samples were processed for H&E staining, or immunolabeled with antibodies against tumor specific markers
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of “initiated” cell to demonstrate that the horizontal
transfer of blood-circulating cancer factors is also applic-
able to human cells [26], confirming thus, the validity of
the “genometastatic” theory in humans [23–25]. Accord-
ing to this theory, carcinogenetic steps such as initiation,
promotion and progression might not represent events
limited to the cells forming the primary tumor, but may
actually be a process reproducible through cancer fac-
tors, shed by primary tumors and carried through the
blood, to susceptible cells, located at metastatic sites [5,
7, 10–16]. In order to strengthen the validity of this al-
ternative metastatic pathway in humans, we used fibro-
blasts, which are among the most represented cells in
human body and central players at metastatic sites [33,
34]. In addition, these cells display a high level of plasti-
city [35]. We induced a BRCA1 oncosuppressor muta-
tion to reproduce an in vitro model that would be as
close as possible to what it is encountered in real clinical
scenarios. We hypothesized that not only immortal cells,
as previously demonstrated [23–26], but also any human
cell carrying a single oncosuppressor mutation might
represent a target cell susceptible of malignant trans-
formation if exposed to blood-circulating cancer factors.
The observation that BRCA1-KO fibroblasts cultured in
cancer patients’ sera displayed oncogenic properties such
as increased proliferation potential and ability to form
tumors following subcutaneous injection into NOD/
SCID mice supports the belief that truly a horizontal
transfer of cancer material might have been overlooked
when trying to understand metastatic disease. Moreover,
the discovery that BRCA1-KO fibroblasts change their
fate completely and turn into colon cancer cells and
pancreatic cancer cells, when exposed to serum derived
from patients affected by metastatic colon and pancre-
atic cancer, strengthen the belief of the authors, that
similarity doesn’t imply sameness and therefore meta-
static cells might not necessarily be only cells detaching
from primary tumors. In line with this concept, the mo-
lecular profiles of primary and metastatic lesions are not
usually identical and therefore, at least theoretically, the
possibility that metastases might not be deriving from
the same cells is still open [36–39]. The data gathered in
our study prove that any cell as long as it is “initiated”
Table 3 Summary of the immunohistochemistry analyses of the
xenografts obtained with cancer patients’ serum-treated BRCA1-
KO fibroblasts
Cases Xenograft Phenotype Differentiation Markers








































































































Fig. 4 Cancer patient sera permanently transformed BRCA1-KO
fibroblasts. a BRCA1-KO fibroblasts were treated with cancer patient
serum for 2 weeks. Cells were then transferred to regular culture
medium (10 % FBS-supplemented DMEM-F12 medium with 1 %
antibiotics) for 2 weeks. Cells were injected subcutaneously into
NOD/SCID mice. 4 weeks after cells transplantation, mice were
euthanized and the tumors photographed. Representative pictures
are shown. b Formalin-fixed paraffin-embedded xenotransplants
samples were processed for H&E staining
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has the potentials to incorporate in its genome “signal-
ing” factors, change its fate and acquire aberrant pheno-
typical traits identical or similar to the source of the
signaling factors.
To our knowledge, this is the first study to demon-
strate the transformation of human fibroblasts carrying a
single oncosuppressor mutation (i.e., BRCA1) into colon
cancer or pancreatic cancer cells after exposure to serum
of patients with metastatic colon or metastatic pancre-
atic cancer. This result becomes even more striking and
fascinating when considering that the recovery test indi-
cated that the phenotypical modifications were indeed
permanent and not related to a transient alteration of
the genetic asset of the cells. In other words, a short ex-
posure to cancer factors present in the serum seems to
have been strong enough to overcome the repair
mechanisms of the treated cells. The main implication
of this stable modification of the genome of human cells
is that at least in vitro, metastatic transformation,
through horizontal transfer, is not a theory anymore but
a fascinating reality. The scientific soundness of this data
is corroborated by the evidence brought about in our ex-
periments that the malignant transformation would be
unlikely to be secondary to an innate instability of the fi-
broblasts caused by the BRCA1 mutation. In fact, the ex-
posure of the BRCA1-KO cells to healthy serum never
made them susceptible of malignant transformation, con-
firming the known notion that a single mutation is not
able to trigger the cascade of events that leads to tumori-
genesis [40].
In our study, we documented, for the first time, a sig-




Fig. 5 BRCA1-KO fibroblasts internalized exosomes more efficiently than control cells. a Exosomes were isolated as described under Methods.
Representative micrographs of transmission electron microscopy on cancer patient sera exosome preparations. The image showed small vesicles
of approximately 50–120 nm in diameter. Scale bars 100 nm. b NanoSight analysis of samples prepared as in (a). The size was centered around
94 nm in diameter. c Confocal microscopy monitoring of PKH-26-labeled exosome uptake in vitro into BRCA1-KO fibroblasts, control fibroblasts,
and HEK293 cells. Note that exosomes internalized more in BRCA1-KO cells. They were dispersed in the cytoplasm and tended to form aggregates
in the perinuclear regions. d The number of PKH-26-labeled exosomes (dots) was counted. Data are expressed as relative number (Rel. Num.) of
exosomes per cell compared to that in control fibroblasts. In the insert, data are expressed as mean +/− SD (n = 6 exosome preparations; P =
0.032 for HEK293 cells compared to control fibroblasts, P = 0.028 for BRCA1-KO fibroblasts compared to control fibroblasts, and
P = 0.35 for HEK293 cells compared to BRCA1-KO fibroblasts)
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BRCA1-KO fibroblasts and HEK293 cells when com-
pared to wild type fibroblasts. This finding noted only in
cells carrying a single oncosuppressor mutation suggests
a potential role that oncosuppressor genes might have in
exosomes trafficking. Perhaps, they might protect the in-
tegrity of the cellular genome not only by repairing
DNA damages and controlling cell cycle checkpoints
[27, 41], but also by blocking the uptake of extracellular
mutating material and thus preventing their integration
in the genome with subsequent DNA alterations. Al-
though we reported an increased uptake of cancer de-
rived exosomes in oncosuppressor mutated cells, their
putative role in the documented malignant transform-
ation of the cells yet has to be determined as well as the
true nature of all the factors involved in the transfer of
malignant traits. While cancer cells-derived circulating
factors (i.e., DNA, mRNA, miRNA, proteins) were de-
tected in the blood of cancer patients, and their regula-
tory role in cancer progression and development were
reported in many studies [16, 22, 32, 42, 43] still their
respective roles have to be fully defined. If on one hand,
it has been reported that exosomes originating from the
primary tumor paves the way for organ-specific metasta-
sis by preparing a niche for the engraftment of circulat-
ing cancer cells, [5–7, 9], on the other hand, the results
of our study might offer a different prospective, which
do not exclude, but might integrate the conventional
view on metastasis.
The inability of the BRCA1-KO fibroblasts to fully dif-
ferentiate in all cancer phenotypes is a limitation of our
study. In our view, this failure is not perceived necessar-
ily as a weakness of the theory but it is perceived as
awareness that the genometastatic process is not under-
stood in its entirety. When we exposed HEK293 to can-
cer patients’ sera the cells turned only into poorly
differentiated carcinomas regardless of the type of can-
cer studied [26]. The exposure of BRCA1-KO fibroblasts
has added value to the genometastatic theory since we
have observed a full differentiation into at least two can-
cer cell lineages (colon and pancreas). We are planning
to repeat the experiments with different cells and differ-
ent single oncosuppressor mutations to see if the hori-
zontal transformation targets different types of cells in
different organs and at different stages of their physio-
logical differentiation according to the type of cancer.
Conclusion
The data presented in this study support the hypothesis
that any human cells carrying a single oncosuppressor
mutation is capable of integrating cancer factors carried
in the blood of cancer patients and undergo complete
malignant transformation. The evidence shown in our
experiments that uptake of cancer-derived exosomes is
significantly increased in these cells suggests a possible
role that oncosuppressor genes might have in exosomes
trafficking.
The reported findings support the notion of the pos-
sible role of a non-classical pathway to explain cancer
traits exchange between malignant and non-malignant
cells that may have implications during cancer progres-
sion and metastasis. Based on these results, the hypoth-
esis that dissemination and migration of cancer cells
from primary tumors might not be the only mechanism
to explain metastases seems rational and merits further
study.
Additional files
Additional file 1: Figure S1. Methodology design followed to knock-out
BRCA1 in fibroblasts. pX-458 plasmid was used as a vector for CRISPR-Cas9
system for BRCA1 knocking down. Human fibroblasts were transfected using
lipofectamine 3000 (A). Transfected fibroblasts with sgBRCA1-pX458 or
empty pX-458 vectors were sorted using a FACSAria cell sorter based
on their GFP positivity. Only GFP positive cells were obtained and expanded
in culture (B). (i) Naïve fibroblasts were gated as negative fraction (GFP
negative fibroblasts). (ii) Fraction of cells sorted as control fibroblasts
(empty pX-458 vector-transfected cells). (iii) Fraction of cells sorted as
sgBRCA1-pX458 transfected fibroblasts (BRCA1-KO). Transfection efficiency
showed percentage of 4–6 %. Fibroblasts were treated with cancer patients’
serum or healthy individual serum. Treated cells were analyzed for their in
vitro proliferation or injected into NOD/SCID mice for tumor growth
potential. (PPT 524 kb)
Additional file 2: Figure S2. Validation of BRCA1 Knockout in human
fibroblasts. (A) Surveyor nuclease assay was performed as described
under Materials and Methods. DNA was extracted from sorted fibroblasts.
After amplification, DNA was denatured, reannealed and subjected to
endonuclease digestion. Digestion products were run on 1 % agarose
gel. Only with DNA extracted from sgBRCA1-transfected fibroblasts, we
detected 3 bands: the full-length PCR product (i) and the digestion products
(ii and iii). Note that the cumulative size of bands ii and iii equals the size of
band i. (B) Western blot analysis of proteins extracted from control
fibroblasts (empty vector transfected) and BRCA1-KO fibroblasts. Note
that BRCA1 signal is absent in BRCA1-KO fibroblasts. (*) points to the
BRCA1 signal. (PPT 265 kb)
Additional file 3: Table S1. List of antibodies used in this study. Table
S2. BRCA1 guide sequence as designed by the CRISPR Design Tool. Table
S3. Analyses of off-target sequences of the BRCA1 guide. (DOC 58 kb)
Additional file 4: Figure S3. Cancer patient sera induced the
transformation of BRCA1-KO fibroblasts. BRCA1-KO fibroblasts were treated
with cancer patient sera for 2 weeks (6 Cases). Treated cells were injected
into NOD/SCID mice that were followed for 4 weeks for tumors growth.
Developing tumors were excised and photographed. (PPT 189 kb)
Additional file 5: Figure S4. Cancer patient sera changed the fate of
BRCA1-KO fibroblasts. BRCA1-KO fibroblasts were treated with CRC-LM
patient sera for 2 weeks (Cases G, H and I). Treated cells were injected
into NOD/SCID mice that were followed for 4 weeks for tumors growth.
Generated tumors were processed for H&E staining, or immunolabeled
with antibodies against tumor specific markers. (PPT 36551 kb)
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